title: Drug-Drug Interactions When Switching Between Intravenous and Oral P2Y12Receptor Inhibitors: How Real Is It?
authors.affiliation: University of Florida College of Medicine-Jacksonville, Jacksonville, Florida.
authors.forename: Fabiana
authors.initials: F
authors.lastname: Rollini
authors.affiliation: University of Florida College of Medicine-Jacksonville, Jacksonville, Florida.
authors.forename: Francesco
authors.initials: F
authors.lastname: Franchi
authors.affiliation: University of Florida College of Medicine-Jacksonville, Jacksonville, Florida. Electronic address: dominick.angiolillo@jax.ufl.edu.
authors.forename: Dominick J
authors.initials: DJ
authors.lastname: Angiolillo
mesh_terms: D054058:Acute Coronary Syndrome; D000241:Adenosine; D004347:Drug Interactions; D010975:Platelet Aggregation Inhibitors; D000068799:Prasugrel Hydrochloride; D058921:Purinergic P2Y Receptor Antagonists; D058925:Receptors, Purinergic P2Y12; D013988:Ticlopidine
chemical_list: D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D058925:Receptors, Purinergic P2Y12; D000068799:Prasugrel Hydrochloride; D000241:Adenosine; D013988:Ticlopidine
keywords: cangrelor; drug-drug interactions; prasugrel; switching; ticagrelor